Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/425"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_type | |
| ?:Evidence_value |
"3.899"
|
| ?:content |
"Route of administration: oral
study duration: 2 days treatment w/ triazolam (TRZ) alone (.25mg 1xday) followed by 7 days treatment with nevazodone alone (200mg, bid); followed by two days dosing with nevazodone + TRZ
population: 12 male
ages:23-38
"
Mean triazolam peak concentration values increased (p = 0.003) from 2.33 to 3.88 ng/ml when triazolam was administered alone and in combination with nefazodone, respectively. Corresponding mean triazolam area under the curve values increased (p < 0.001) from 8.14 to 31.74 ng.h/ml.""
|
| dc:creator | |
| dc:date |
"10/29/2007 11:25:10"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ nefazodone_increases_auc_triazolam, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1234 }